Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07395050 · ClinicalTrials.gov registry record · Early Phase 1
Autologous CD6-CAR Treg Cells for Patients With Stage 3 Type 1 Diabetes
A Early Phase 1 study, sponsored by City of Hope Medical Center.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT07395050 is a Early Phase 1 study that has not yet begun recruiting, run by City of Hope Medical Center. The registered enrollment target is 6 participants.
The verdict
NCT07395050, a Early Phase 1 study, has not yet begun recruiting, sponsored by City of Hope Medical Center.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Type 1 diabetes (T1D) is a persistent and gradually increasing genetic autoimmune disease requiring life-long management. The disease commonly impacts children. However, a quarter of cases are diagnosed in adults. The pancreatic islet beta-cells are responsible for producing insulin, a peptide hormone that is involved in the tight regulation of blood glucose levels. In T1D, the beta-cells are mistakenly destroyed by autoreactive T cells resulting in insulin deficiency and an inability to regulate blood glucose levels. The cause for such an autoimmune reaction to beta-cells is under active investigation. T regulatory cells (Tregs), are specialized immune cells that typically act to control your immune system. Tregs can be modified in the laboratory to recognize and deactivate T1D-causing cells. This process is done by inserting a piece of DNA (the molecules inside cells that carry genetic information and pass it from one generation to the next) into the Tregs. A non-infectious virus called a lentivirus will carry the piece of DNA into the cells that were collected from a donor. Tregs are then grown to large numbers in the laboratory and stored for treatment of T1D. It is not known whether these Tregs cells will treat T1D.
Interventions
- DRUG AutoCD6-CAR Treg cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2026-09-14 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07395050
The ClinicalTrials.gov registry entry for NCT07395050 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AutoCD6-CAR Treg cells is the first listed.
NCT07395050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07395050 about?
NCT07395050 is a clinical study titled "Autologous CD6-CAR Treg Cells for Patients With Stage 3 Type 1 Diabetes". Type 1 diabetes (T1D) is a persistent and gradually increasing genetic autoimmune disease requiring life-long management. The disease commonly impacts children. However, a quarter of cases are diagnosed in adults. The pancreatic islet beta-cells are responsible for producing insulin, a peptide hormo...
What is the current status of trial NCT07395050?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2026-06-01. Estimated completion is 2026-09-14.
What interventions are being tested in trial NCT07395050?
The interventions under investigation include: AutoCD6-CAR Treg cells (DRUG).
Who is sponsoring clinical trial NCT07395050?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.